Methods paper for the landmark iStopMM trial now published
Binding site is pleased to announce that the methods paper for the landmark iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) study has now been published.
In January 2016, the iStopMM study, commenced work on screening all adults over the age of 40 in Iceland, with the aim of preventing Multiple Myeloma before it develops.
Using Binding Site's revolutionary Freelite assay and Optilite analyser, over 75,000 samples have been successfully tested at the Binding Site’s state of the art laboratories in Birmingham, UK. The publication of this work marks a huge milestone for the project team and Binding Site.
Commenting on the article, Stefan Wolf, CEO, Binding Site said “It is a privilege to be involved in a study of this size and calibre. Ultimately, this pivotal study will be key to answer two important questions: is population-based screening for MGUS (Monoclonal Gammopathy of Undetermined Significance) beneficial? And what’s the optimum monitoring approach for patient management?
At Binding Site, our mission, above all else, is to have the patient at the heart of everything we do. Supporting this trial reinforces that commitment as we endeavour to continually improve the approach and strategy for patient management, to achieve the best possible outcome.”
View the methods paper, here.
Find out more about iStopMM, here.